≡ Risteys
R8

Documentation Changelog GitHub Contact & Feedback

Systemic lupus erythematosus, unspecified

DOID EFO MESH SNOMED PheWeb

SLE_NOS

systemic lupus erythematosus: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.

Endpoint definition

↥
FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector

Check conditions None

356077

diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 M32.9
Hospital discharge: ICD-9 $!$
Hospital discharge: ICD-8 $!$
Cause of death: ICD-10 M32.9
Cause of death: ICD-9 $!$
Cause of death: ICD-8 $!$

779

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

779

diagram downward connector

Check minimum number of events None

779

diagram downward connector

Include endpoints None

779

diagram downward connector
SLE_NOS

Extra metadata

First used in FinnGen datafreeze DF2
Parent code in ICD-10 M32
Name in latin Lupus erythematosus disseminatus non specificatus

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 779 663 116
Unadjusted prevalence (%) 0.22 0.33 0.07
Mean age at first event (years) 47.40 46.40 53.13

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.03 2.07 [1.01, 4.24] 4.6e-2 61
15 years 0.01 1.39 [0.69, 2.79] 3.6e-1 26
5 years 0.00 3.19 [1.61, 6.32] 8.9e-4 18
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: SLE_NOS – Systemic lupus erythematosus, unspecified
GWS hits:

Survival analyses between endpoints

↥

Plot

before Systemic lupus erythematosus, unspecified
after Systemic lupus erythematosus, unspecified

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Systemic lupus erythematosus, unspecified

↥